Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

980 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.
Aschner P, Chan J, Owens DR, Picard S, Wang E, Dain MP, Pilorget V, Echtay A, Fonseca V; EASIE investigators. Aschner P, et al. Among authors: fonseca v. Lancet. 2012 Jun 16;379(9833):2262-9. doi: 10.1016/S0140-6736(12)60439-5. Epub 2012 Jun 9. Lancet. 2012. PMID: 22683131 Clinical Trial.
Triple combination of insulin glargine, sitagliptin and metformin in type 2 diabetes: the EASIE post-hoc analysis and extension trial.
Chan JC, Aschner P, Owens DR, Picard S, Vincent M, Dain MP, Pilorget V, Loizeau V, Echtay A, Fonseca V. Chan JC, et al. Among authors: fonseca v. J Diabetes Complications. 2015 Jan-Feb;29(1):134-41. doi: 10.1016/j.jdiacomp.2014.08.007. Epub 2014 Aug 27. J Diabetes Complications. 2015. PMID: 25283485 Free article. Clinical Trial.
Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial.
Rosenstock J, Fonseca V, Schinzel S, Dain MP, Mullins P, Riddle M. Rosenstock J, et al. Among authors: fonseca v. J Diabetes Complications. 2014 Sep-Oct;28(5):742-9. doi: 10.1016/j.jdiacomp.2014.04.003. Epub 2014 Apr 16. J Diabetes Complications. 2014. PMID: 24856612 Free PMC article. Clinical Trial.
COVID-19 in people living with diabetes: An international consensus.
Caballero AE, Ceriello A, Misra A, Aschner P, McDonnell ME, Hassanein M, Ji L, Mbanya JC, Fonseca VA. Caballero AE, et al. Among authors: fonseca va. J Diabetes Complications. 2020 Sep;34(9):107671. doi: 10.1016/j.jdiacomp.2020.107671. Epub 2020 Jul 6. J Diabetes Complications. 2020. PMID: 32651031 Free PMC article. Review.
Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1).
Raz I, Fonseca V, Kipnes M, Durrwell L, Hoekstra J, Boldrin M, Balena R. Raz I, et al. Among authors: fonseca v. Diabetes Care. 2012 Mar;35(3):485-7. doi: 10.2337/dc11-1942. Epub 2012 Feb 1. Diabetes Care. 2012. PMID: 22301126 Free PMC article. Clinical Trial.
Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.
Fonseca V, Staels B, Morgan JD 2nd, Shentu Y, Golm GT, Johnson-Levonas AO, Kaufman KD, Goldstein BJ, Steinberg H. Fonseca V, et al. J Diabetes Complications. 2013 Mar-Apr;27(2):177-83. doi: 10.1016/j.jdiacomp.2012.09.007. Epub 2012 Oct 30. J Diabetes Complications. 2013. PMID: 23116881 Clinical Trial.
Comparing diabetes drugs--helping clinical decisions?
Thethi T, Fonseca V. Thethi T, et al. Among authors: fonseca v. Lancet. 2013 Jan 12;381(9861):93-4. doi: 10.1016/S0140-6736(12)61576-1. Epub 2012 Nov 7. Lancet. 2013. PMID: 23141811 No abstract available.
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.
Rosenstock J, Diamant M, Aroda VR, Silvestre L, Souhami E, Zhou T, Perfetti R, Fonseca V; LixiLan PoC Study Group. Rosenstock J, et al. Among authors: fonseca v. Diabetes Care. 2016 Sep;39(9):1579-86. doi: 10.2337/dc16-0046. Epub 2016 Jun 9. Diabetes Care. 2016. PMID: 27284114 Free PMC article. Clinical Trial.
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G; FIDELIO-DKD Investigators. Bakris GL, et al. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845. Epub 2020 Oct 23. N Engl J Med. 2020. PMID: 33264825 Free article. Clinical Trial.
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM; FIGARO-DKD Investigators. Pitt B, et al. N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956. Epub 2021 Aug 28. N Engl J Med. 2021. PMID: 34449181 Clinical Trial.
980 results